[1] He holds multiple patents relating to genetic testing and treatment for the supposed syndrome that have been licensed through various different corporations.
[4] The term refers to an inborn chemical imbalance that alters the intercellular signaling in the brain's reward process and can manifest itself as one or more behavioral disorders.
Blum is the editor-in-chief of Journal of Reward Deficiency Syndrome and Addiction Science and founded the company that publishes it, United Scientific Group.
Synaptamine has been licensed to LaVita RDS, a company based in Lehi, Utah, of which Blum was the chief scientific officer.
In the past, Blum has sold a variety of supplements and oral sprays through a website called DocBlumInc.
Blum markets a genetic test, the Genetic Addiction Risk Score (GARS), through his company IGENE LLC in partnership with Dominion Diagnostics,[19][17][20] through LifeGen, Inc., where he is chairman of the board and chief scientific officer,[21] and via Geneus Health for whom he also acts chief scientific officer and chairman.
[23] After Blum's departure, Salugen continued under the leadership of Brian Meshkin, latterly CEO of Prove Biosciences, until its demise a year later.